Stocks Health care INVA
NASDAQ · Health careInnoviva, Inc. (INVA)
Innoviva, Inc. brought in $438.3M of revenue over the twelve months to September 30, 2026, up 12.8% from a year earlier. Net income was $193.4M, a net margin of 44.1%. Operating cash flow minus capital spending left $195.8M of free cash flow in fiscal 2025. At September 30, 2026 it held $581.4M in cash against $258.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Innoviva, Inc.
- Net worth
- Innoviva, Inc. has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $411.3M (+14.7% year on year), with net income of $271.2M. Over the 12 months to September 30, 2026: revenue $438.3M, net income $193.4M.
- Cash flow
- In fiscal 2025 operations brought in $196.9M of cash; after $1.1M of capital spending, free cash flow was $195.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Innoviva, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Innoviva, Inc. does
Innoviva, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INVA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $411.3M | $271.2M | $3.30 | $195.8M |
| 2024 | $358.7M | $23.4M | $0.36 | $188.4M |
| 2023 | $310.5M | $179.7M | $2.20 | $140.7M |
| 2022 | $331.3M | $213.9M | $2.37 | $201.7M |
| 2021 | $391.9M | $265.9M | $2.87 | $363.8M |
| 2020 | $336.8M | $224.4M | $2.02 | $313.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INVA ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2021 | n/a | $0 | 0% |
| 2020 | n/a | $0 | 0% |
| 2019 | n/a | $11K | 0% |
| 2018 | n/a | $80K | 0% |
| 2017 | $0.00 | $281K | 0% |
| 2016 | $0.00 | $960K | 2% |
Latest SEC filings
What Innoviva, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 1.6% to $106.1M versus the same quarter last year; diluted EPS -$1.03 versus $1.08.
- November 4, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 19% to $119.6M versus the same quarter last year; diluted EPS -$1.14 versus $0.77.
- August 5, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- May 18, 2026
- May 13, 2026Activist stake changed SCHEDULE 13D/A
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 11% to $98M versus the same quarter last year; diluted EPS $2.22 versus -$0.74.
- May 6, 2026
What is INVA worth? A DCF from its reported cash flow
Insider trades
What the people running Innoviva, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 20, 2026 | Raifeld PavelChief Executive Officer, Director | Shares withheld for tax | 1,130 | $23.7K |
| August 20, 2026 | Basso StephenChief Financial Officer | Shares withheld for tax | 558 | $11.7K |
| August 20, 2026 | Zhen MarianneChief Accounting Officer | Shares withheld for tax | 1,127 | $23.7K |
| May 20, 2026 | Zhen MarianneChief Accounting Officer | Shares withheld for tax | 1,127 | $25.1K |
| May 20, 2026 | Raifeld PavelChief Executive Officer, Director | Shares withheld for tax | 1,130 | $25.1K |
| May 20, 2026 | Basso StephenChief Financial Officer | Shares withheld for tax | 559 | $12.4K |
| May 18, 2026 | Linden JosephineDirector | Received as pay | 5,733 | - |
| May 18, 2026 | Linden JosephineDirector | Received as pay | 9,461 | - |
Who owns INVA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Innoviva, Inc.13D, may seek influence with 1 related filers | 82.7% | May 13, 2026 |
| BlackRock, Inc.13G, passive | 15.4% | October 27, 2026 |
| Dimensional Fund Advisors LP13G, passive | 5.8% | January 21, 2026 |
| Vanguard Portfolio Management13G, passive | 5.79% | April 29, 2026 |
| Renaissance Technologies LLC13G, passive with 1 related filers | 5.63% | February 12, 2026 |
| Vanguard Capital Management13G, passive | 5.01% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 321 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 12,115,195 | +742,300 |
| Dimensional Fund Advisors LP | 4,494,053 | +57,626 |
| Vanguard Portfolio Management LLC | 4,301,627 | +76,676 |
| Renaissance Technologies LLC | 4,084,850 | -9,278 |
| State Street Corp | 3,397,604 | +286,427 |
| Vanguard Capital Management LLC | 3,646,021 | +138,412 |
| Millennium Management LLC | 3,011,609 | +474,166 |
| Geode Capital Management, LLC | 2,345,259 | +300,986 |
| Systematic Financial Management LP | 2,023,565 | -517 |
| Boston Partners | 1,927,959 | +209,092 |
| Sarissa Capital Management LP | 1,890,604 | -240,346 |
| Bank of America Corp | 1,679,002 | +47,294 |
| Goldman Sachs Group Inc | 1,620,093 | -34,243 |
| American Century Companies Inc | 1,498,044 | -411,977 |
| Marshall Wace, Llp | 1,454,319 | -50,092 |
| Morgan Stanley | 1,225,414 | -88,703 |
| Royce & Associates LP | 1,172,690 | +111,242 |
| Charles Schwab Investment Management Inc | 1,180,164 | +16,451 |
| Two Sigma Investments, LP | 1,032,807 | -451,457 |
| Qube Research & Technologies Ltd | 974,124 | +161,389 |
Insiders
8 insiders reported holding 923,106 shares in total, about $17.5M at the last price.
| Holder | Shares |
|---|---|
| Raifeld PavelChief Executive Officer, Director | 284,799 |
| Haimovitz JulesDirector | 152,692 |
| DiPaolo MarkDirector | 140,492 |
| Schlesinger Sarah J.Director | 140,492 |
| Basso StephenChief Financial Officer | 88,013 |
| Zhen MarianneChief Accounting Officer | 56,389 |
| Small Derek ADirector | 45,035 |
| Linden JosephineDirector | 15,194 |
Questions about INVA
What does Innoviva, Inc. do?
Innoviva, Inc. is a company in the Health care sector, listed on NASDAQ as INVA. Its shares trade on NASDAQ under the ticker INVA.
What is Innoviva, Inc.'s net worth?
Innoviva, Inc. has a market value (market cap) of $1.4B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Innoviva, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $193.4M on revenue of $438.3M, a net margin of 44.1%.
How much revenue does Innoviva, Inc. make?
Over the twelve months to September 30, 2026 Innoviva, Inc. reported revenue of $438.3M. That is 12.8% more than a year earlier.
When did Innoviva, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Innoviva, Inc.'s next earnings report?
Innoviva, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INVA with
Follow INVA
Get an email when Innoviva, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Innoviva, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.